SUPPLEMENTARY INFORMATION:

The following represents the intellectual property to be licensed under the prospective agreement: Korean Patent Application No. 10-2025-0196127, filed December 11, 2025, titled “An Antibody Specifically Binding to Severe Fever with Thrombocytopenia Syndrome Virus Antigen and Use thereof” (NIH Tracking Number E-102-2025-0). All rights in this invention have been assigned to Korea National Institute of Health and the Government of the United States of America.

The prospective patent license will be for the purpose of consolidating the patent rights with Korea National Institute of Health, the co-owner of said rights, for commercial development and marketing. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200-212.

The prospective interinstitutional agreement will include an exclusive license for NIAID's rights in these jointly owned patent rights. It will be sublicensable, and any sublicenses granted by Korea National Institute of Health will be subject to the provisions of 37 CFR part 404.

The subject patent rights are related to novel antibodies and antigen-binding fragments that specifically bind the Severe Fever with Thrombocytopenia Syndrome (SFTS) virus envelope glycoprotein antigen, including Gn- and Gc-targeting antibodies, together with related pharmaceutical and diagnostic compositions for prevention, diagnosis, mitigation, or treatment of SFTS virus infection. The invention arose from a research collaboration between NIAID and Korea National Institute of Health.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and may be granted unless within fifteen (15) days from the date of this published notice, the National Institute of Allergy and Infectious Diseases receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

91 FR 64672